Novo Nordisk ASWBO:NNO2 +1.76%71 3-Year EBITDA Growth Rate is 27.80% as of Mar. 2026, which is 100% above its 10-year median of 13.90. GuruFocus rates WBO:NNO2 with a GF Score™ of 71/100 and a GF Value™ of €120.11 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 814 Drug Manufacturers companies, Novo Nordisk AS ranks better than 77.27% on this metric.
During the past 12 months, Novo Nordisk AS's average EBITDA Per Share Growth Rate was 10.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 27.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 25.90% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 15.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Novo Nordisk AS was 166.20% per year. The lowest was -49.70% per year. And the median was 13.90% per year.
Novo Nordisk AS (WBO:NNO2) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Novo Nordisk AS 3-Year EBITDA Growth Rate Related Terms
WBO:NNO2 vs LLY, JNJ, ABBV: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's 3-Year EBITDA Growth Rate falls into.
Novo Nordisk AS 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 27.80% mean?
Novo Nordisk AS (WBO:NNO2) has a 3-Year EBITDA Growth Rate of 27.80% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Novo Nordisk AS and its competitors. This is 100% above median its historical median of 13.90. According to the industry distribution chart, Novo Nordisk AS ranks #185 out of 814 companies in the Drug Manufacturers industry, placing it in the top 22.7%.
Is Novo Nordisk AS's 3-Year EBITDA Growth Rate too high?
Novo Nordisk AS's current 3-Year EBITDA Growth Rate of 27.80% is 100% above median its 10-year median of 13.90. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Novo Nordisk AS's value of 27.80% is 212.4% above this industry median. Based on the distribution chart, Novo Nordisk AS ranks #185 out of 814 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novo Nordisk AS has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's 3-Year EBITDA Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novo Nordisk AS ranks #185 out of 814 companies for 3-Year EBITDA Growth Rate. This places Novo Nordisk AS in the top 23% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Novo Nordisk AS's value of 27.80% is 212.4% above this benchmark. While the company's 10-year median is 13.90 vs. the industry median of 8.90, Novo Nordisk AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Nordisk AS's current 3-Year EBITDA Growth Rate of 27.80% is 212.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current 3-Year EBITDA Growth Rate is 27.80%, which is 100% above median its own 10-year median of 13.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (WBO:NNO2) is currently considered Significantly Undervalued. The stock's GF Value™ is €120.11, compared to a current price of €43.59 — trading 63.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 27.80%, which is 100% above median its 10-year median of 13.90 and 212.4% above the Drug Manufacturers industry median of 8.90. Novo Nordisk AS's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Novo Nordisk AS (WBO:NNO2), the current 3-Year EBITDA Growth Rate is 27.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (WBO:NNO2) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of €43.59 is trading 63.7% below its estimated GF Value™ of €120.11.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for WBO:NNO2:
3-Year EBITDA Growth Rate: 27.80% (100% above median its 10-year median of 13.90)
GF Value™: €120.11 vs. price of €43.59 (63.7% below fair value)
Industry Position: 212.4% above the Drug Manufacturers median (#185 of 814)
No single metric tells the full story. See the WBO:NNO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
71GF Score
Get the complete analysis for WBO:NNO2
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:NNO2 has been successfully added to your 